- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06955169
Undersøgelse af [177LU] Lu-Dotatate hos voksne med progressiv intrakraniel grad 1-3 meningioma (MOMENTUM-1)
Momentum-1: Et multicenter, randomiseret, åbent mærket, fase II-studie af [177LU] lu-dotatat hos voksne med progressiv intrakraniel grad 1-3 meningioma
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Sylvia C Kurz, MD,PhD
- Telefonnummer: 203-785-5616
- E-mail: Sylvia.Kurz@yale.edu
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92697
- Rekruttering
- University of California, Irvine
-
Ledende efterforsker:
- Daniela Bota, MD, PhD
-
Kontakt:
- Manisha Dandekar
- E-mail: mdandeka@hs.uci.edu
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- University of California San Diego - Moores Cancer Center
-
Ledende efterforsker:
- Jona Hattangadi-Gluth, MD
-
Kontakt:
- Mohammad Amjad
- E-mail: mtamjad@health.ucsd.edu
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- USC Keck School of Medicine
-
Kontakt:
- Christine Duran
- E-mail: duran_c@med.usc.edu
-
Ledende efterforsker:
- Aram Modrek, MD, PhD
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Rekruttering
- Yale University
-
Ledende efterforsker:
- Sylvia Kurz, MD, PhD
-
Kontakt:
- Amy Rodrigues, CCRC
- Telefonnummer: 203-260-9632
- E-mail: amy.rodrigues@yale.edu
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32207
- Rekruttering
- Baptist MD Anderson Cancer Center
-
Ledende efterforsker:
- Michael Olson, MD PhD
-
Kontakt:
- E-mail: CTOinterest@bmcjax.com
-
Underforsker:
- Andre Alvarez, MD PhD
-
Miami, Florida, Forenede Stater, 33146
- Rekruttering
- University of Miami
-
Kontakt:
- Lily Friedman
- E-mail: lxf699@med.miami.edu
-
Ledende efterforsker:
- Marina Kushnirsky, MD
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Baptist Health Medical Group Oncology
-
Ledende efterforsker:
- Matthew Hall, MD
-
Kontakt:
- Nicolas Morales
- E-mail: nicolas.morales1@baptisthealth.net
-
Tampa, Florida, Forenede Stater, 33543
- Rekruttering
- Moffitt Cancer Center
-
Kontakt:
- Abdullah Abdelkawy
- E-mail: Abdullah.abdelkawy@Moffitt.org
-
Ledende efterforsker:
- Andre Luiz Beer Furlan, MD, PhD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30318
- Rekruttering
- Piedmont Healthcare
-
Kontakt:
- Jeff Whorton, BSN,RN
- E-mail: jeff.whorton@piedmont.org
-
Ledende efterforsker:
- Adam Nowlan, MD, MPH
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Indiana University
-
Ledende efterforsker:
- Kathryn Nevel, MD
-
Kontakt:
- Lauren Perrey-Moore, RN
- E-mail: lperry@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Health Care
-
Kontakt:
- Kristin West, RN, BSN
- E-mail: kristin-gaimari-varner@uiowa.edu
-
Ledende efterforsker:
- Kristin Plichta, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber/Harvard Cancer Center
-
Kontakt:
- Kathryn Partridge
- E-mail: Kathryn_Partridge@DFCI.HARVARD.EDU
-
Ledende efterforsker:
- Gilbert Youssef, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan Rogel Cancer Center
-
Kontakt:
- Jen Thomas
- E-mail: jennifkt@med.umich.edu
-
Ledende efterforsker:
- Sean Miller, MD
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Hospital
-
Kontakt:
- Jennifer Cooper
- E-mail: jcoope13@hfhs.org
-
Ledende efterforsker:
- Tobias Walber, MD, PhD, MPH
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU Lagone Health
-
Ledende efterforsker:
- Marissa Barbaro, MD
-
Kontakt:
- Olga Garduno-Ortega
- E-mail: Olga.Garduno-Ortega@nyulagone.org
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 22708
- Rekruttering
- Duke University Medical Center
-
Ledende efterforsker:
- Margaret Johnson, MD
-
Kontakt:
- Kelly Moulton
- E-mail: kelly.moulton@duke.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Rekruttering
- Thomas Jefferson University Hospital
-
Ledende efterforsker:
- Iyad Alnahhas, MD
-
Kontakt:
- Oleksandr Kolesnikov
- Telefonnummer: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Kontakt:
- Wathoo Chetna
- E-mail: cwathoo@mdanderson.org
-
Ledende efterforsker:
- Carlos Kamiya-Matsuoka, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
Kontakt:
- Bailee Fritz
- E-mail: bfritz@mcw.edu
-
Ledende efterforsker:
- Michael Straza, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
STEP 1 REGISTRATION
- Aged >= 18 years
- Histologically confirmed diagnosis of WHO grade 1-3 meningioma
- Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
- The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
- Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
- Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion
- The following scans must be available for submission for central radiology review:
- Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
- Progression gadolinium-enhanced MRI brain scan
STEP 2 REGISTRATION
- Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion.
- [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
- Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
- Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
- Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
- Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
- AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
- Potassium within normal limits.
Exclusion Criteria:
- Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
- Patients with radiation-associated meningiomas.
- Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
- Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
- Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
- Patients requiring immediate local therapy (e.g. surgical resection).
- Surgical procedure within the timeframes listed below, prior to step 2 registration.
- 28 days from any prior craniotomy
- 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
- Treatment within the timeframes specified below, prior to step 2 registration.
- 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
- 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
- A target lesion is excluded if it has received any of the following:
- More than 2 total prior courses of radiation
- More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
- Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.
For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.
- All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
- Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
- Active infection requiring current use of intravenous therapy with antibiotics.
- Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
- An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
- Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: [177Lu]Lu-DOTATATE
Study participants receive [177Lu]Lu-DOTATATE |
The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
Andre navne:
|
|
Andet: Control
Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression |
Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsramme: Assessed up to 4 years
|
Proportion of patients alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival at 6 months (PFS-6)
Tidsramme: 6 months
|
Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
6 months
|
|
Overall Survival at 12 months (OS-12)
Tidsramme: 12 months
|
Proportion of participants alive at 12 months |
12 months
|
|
Overall survival (OS)
Tidsramme: Assessed up to 4 years
|
Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
|
Progression-free Survival after cross-over (PFS2)
Tidsramme: Assessed up to 4 years
|
Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
Assessed up to 4 years
|
|
Disease Control Rate (DCR)
Tidsramme: Assessed up to 4 years
|
Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
Assessed up to 4 years
|
|
Objective response rate (ORR)
Tidsramme: Assessed up to 4 years
|
Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
Assessed up to 4 years
|
|
Number of participants by highest grade treatment-emergent adverse event (TEAE):
Tidsramme: Assessed up to 4 years
|
Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Assessed up to 4 years
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Sylvia C Kurz, MD, PhD, Yale University
- Ledende efterforsker: Erik P Sulman, MD,PhD, Duke University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, nervevæv
- Neoplasmer i nervesystemet
- Neoplasmer, vaskulært væv
- Meningeale neoplasmer
- Neoplasmer i centralnervesystemet
- Meningiom
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Azoler
- Indoler
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Makrolider
- Lactoner
- Pyrroles
- Sirolimus
- Sunitinib
- Bevacizumab
- Everolimus
- Lutetium Lu 177 Dotatate
Andre undersøgelses-id-numre
- RTOG 3523
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .